Opportunities and Challenges for Generic Drugs in the UK 2007

Summary

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the musculoskeletal sector. The report includes unique sales forecasts by major product.

The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product. Click here for more information. This chapter is available separately.

The musculoskeletal market is the sixth largest therapeutic category by sales and generated over US$228 billion (+0.8% YoY) in 2005. Sales grew strongly in the US and Europe which accounted for 54% and 23% of sales however, sales have slowed significantly, largely due to the withdrawal of a number of COX-2 inhibitors during 2004 and early 2005.

Two of the largest segments of the musculoskeletal market are rheumatoid arthritis (anti-rheumatics) and osteoporosis (bone calcium regulators). The remaining sales are derived from the treatment of a mixture of aetiologies such as anti-inflammatory conditions and muscle relaxants.

Please Note: The publisher will not fulfil orders to a personal email address, you must supply a work or business address.

Contents

• • Foreword
  • Introduction
  • Background to the Market
  • Geography
  • Political Overview
  • Economic Overview
  • Demographics
  • Demographic indicators
  • The UK Healthcare System
  • Organisation
  • Primary Care Trusts
  • Healthcare expenditure
  • Hospital beds
  • Medical personnel
  • The UK Generics Market
  • In Context: the UK Pharmaceutical Market
  • Market Structure
  • Reimbursement
  • Pricing: the PPRS
  • Unbranded Generic Pricing
  • 2005 generics reimbursement scheme
  • Generic price reductions for four major drugs
  • DOH Holds consultations regarding branded generics in the PPRS
  • Regulation of Pharmaceuticals
  • Generic regulation
  • Intellectual Property
  • Supplementary Protection Certificates
  • Prescription Medicines Market
  • England
  • Generic Market Size
  • Generic Prescribing
  • Scotland
  • Wales
  • Outlook for Future Growth
  • Investigations into price fixing
  • Department of Health
  • Ranbaxy and Merck settle DOH claims
  • Serious Fraud Office
  • Overview of the Domestic Industry
  • Total Turnover
  • UK Turnover
  • Operating Profit
• Generic Drugs In The UK
  • Net Profit
  • Employees
  • Sales per Employee
  • Leading Players in the Market
  • Actavis UK Ltd
  • Actavis worldwide
  • Actavis in the UK
  • Products on the UK market
  • Financial indicators
  • Arrow Generics Ltd
  • Products on the UK market
  • Financial indicators
  • Bristol Laboratories
  • Products on the UK Market
  • Financial indicators
  • Crescent Pharma
  • Products on the UK market
  • Financial indicators
  • Dr Reddy's Laboratories (UK) Ltd
  • Dr Reddy's worldwide
  • UK operations
  • Financial indicators
  • Focus Pharmaceuticals
  • Products in the UK
  • Financial Indicators
  • Generics (UK) Ltd
  • Merck Generics worldwide
  • UK Operations
  • Products in the UK market
  • Financial indicators
  • Genus Pharmaceuticals
  • Products
  • Financial indicators
  • Goldshield Pharmaceuticals Ltd
  • Goldshield Group
  • Products
  • Financial indicators
  • Kent Pharmaceuticals
  • Products
  • Financial indicators
  • Perrigo UK Ltd
  • Products
  • Financial indicators
  • Pliva Pharma Ltd
• Generic Drugs In The UK
  • Pliva worldwide
  • Pliva in the UK
  • Financial indicators
  • Ranbaxy (UK) Ltd
  • Ranbaxy worldwide
  • Ranbaxy in the UK
  • Financial indicators
  • ratiopharm UK
  • ratiopharm worldwide
  • ratiopharm in the UK
  • Financial indicators
  • Rosemont Pharmaceuticals
  • Products
  • Financial indicators
  • Sandoz
  • Sandoz worldwide
  • Sandoz in the UK
  • Products
  • Financial indicators
  • Teva UK
  • Teva worldwide
  • Teva in the UK
  • Financial indicators
  • Winthrop Pharmaceuticals
  • Winthrop worldwide
  • Winthrop in the UK
  • Products
  • Financial indicators
  • Wockhardt UK Ltd
  • Wockhardt worldwide
  • Wockhardt in the UK
  • Products
  • Financial indicators
  • Marketing Authorisations in 2006
  • Trading Companies
  • Wholesaling
  • AAH Pharmaceuticals Ltd
  • Alliance Boots (formerly Alliance Unichem)
  • Exclusive Distribution Deal with Pfizer
  • Mawdsleys
  • Phoenix Healthcare Distribution Ltd
  • Retailing
  • Major Pharmacy Chains
  • Alliance Boots
• Generic Drugs In The UK
  • Lloyds Pharmacy
  • Superdrug
  • Appendix 1: Analysis of Leading Patent-Expired Drugs
  • Amisulpride
  • Risperidone
  • Ramipril
  • Glimepiride
  • Ondansetron
  • Sumatriptan
  • Amlodipine
  • Citalopram
  • Fluconazole
  • Gabapentin
  • Lamotrigine
  • Meloxicam
  • Meloxicam
  • Sertraline
  • Tamsulosin
  • Terbinafine
  • Appendix 2: Rising Use of Generics in the UK Statins Market
  • Market Developments
  • Atorvastatin
  • Fluvastatin
  • Pravastatin
  • Rosuvastatin
  • Simvastatin
  • Appendix 3: Generics in the UK PPI Market
  • Esomeprazole
  • Lansoprazole
  • Omeprazole
  • Pantoprazole
  • Rabeprazole sodium
  • Appendix 4: Sources
  • Espicom Sources
  • UK Government Sources
  • Industry Sources
  • Appendix 5: DIRECTORY
  • Regulators
  • Trade Bodies
  • Manufacturers